本文選題：卵巢癌　切入點(diǎn)：養(yǎng)正桂苓湯　出處：《黑龍江中醫(yī)藥大學(xué)》2017年碩士論文

【摘要】：目的:觀察自擬養(yǎng)正桂苓湯聯(lián)合TP方案對(duì)卵巢癌的療效及T細(xì)胞免疫功能的影響。方法:采用完全隨機(jī)分組法將納入的60例病例分為治療組和對(duì)照組,其中對(duì)照組病例30例,予紫杉醇+順鉑化療,治療組病例30例,在西醫(yī)化療基礎(chǔ)上配合服用自擬養(yǎng)正桂苓湯。化療采用21天方案,連續(xù)觀察2個(gè)周期,中藥口服從化療第一天開始,日2次各150ml早晚分服,連服6周。觀察兩組患者的中醫(yī)證候積分、卡氏評(píng)分、腫瘤標(biāo)志物CA125、T細(xì)胞免疫功能及血常規(guī)、肝腎功能等安全性指標(biāo)。結(jié)果:1.中醫(yī)療效評(píng)定:治療組總有效率為86.67%,對(duì)照組總有效率為60.00%,經(jīng)統(tǒng)計(jì)p0.01,差異具有顯著統(tǒng)計(jì)學(xué)意義。2.KPS評(píng)分:兩組治療后與治療前比較,p值均小于0.0 1,差異具有顯著統(tǒng)計(jì)學(xué)意義;且治療后兩組間比較,P=0.0020.01,差異具有顯著統(tǒng)計(jì)學(xué)意義。3.腫瘤標(biāo)志物CA125:兩組治療后與治療前比較,p值均小于0.01,差異具有顯著統(tǒng)計(jì)學(xué)意義;且治療后兩組間比較,p=0.0060.01,差異具有顯著統(tǒng)計(jì)學(xué)意義。4.細(xì)胞免疫功能:兩組治療后與治療前比較,p值均小于0.01,差異具有顯著統(tǒng)計(jì)學(xué)意義;且治療后兩組間比較p0.01,差異具有顯著統(tǒng)計(jì)學(xué)意義。5.在不良反應(yīng)發(fā)生率上,兩組在白細(xì)胞、谷丙轉(zhuǎn)氨酶、谷草轉(zhuǎn)氨酶及肌酐比較上,p均大于0.05,差異無統(tǒng)計(jì)學(xué)意義。結(jié)論:1.自擬養(yǎng)正桂苓湯聯(lián)合TP方案能夠降低卵巢癌患者血清CA125水平。2.自擬養(yǎng)正桂苓湯聯(lián)合TP方案能夠調(diào)節(jié)T細(xì)胞的表達(dá)水平,改善卵巢癌患者的免疫狀態(tài)。3.自擬養(yǎng)正桂苓湯聯(lián)合TP方案能夠改善氣虛血瘀型卵巢癌患者的臨床癥狀,提高生活質(zhì)量。
[Abstract]:Objective: to observe the effect of Yangzhenggui Ling decoction combined with TP regimen on ovarian cancer and T-cell immune function. Methods: 60 cases were randomly divided into treatment group and control group, including 30 cases in control group. Paclitaxel cisplatin chemotherapy was given. 30 cases in the treatment group were treated with self-made Yangzhenggui decoction on the basis of western medicine chemotherapy. The chemotherapy was carried out with a 21-day regimen and two consecutive cycles of observation. The oral administration of traditional Chinese medicine began on the first day of chemotherapy. 150ml was taken twice a day in the morning and evening for 6 weeks. The TCM syndromes score, Karschoff score, tumor marker CA125 T cell immune function and blood routine were observed in the two groups. Results: the total effective rate of the treatment group was 86.67, the total effective rate of the control group was 60.000.The difference was statistically significant (p0.01). 2. KPS score: the two groups were compared with the treatment group before and after treatment. The values were less than 0.01, the difference was statistically significant. The difference between the two groups after treatment was statistically significant (P < 0.01). The tumor marker CA125 was less than 0.01in both groups after treatment and before treatment, and the difference was statistically significant. After treatment, the difference between the two groups was statistically significant. 4. The cellular immune function: after treatment and before treatment, the P value of the two groups was less than 0.01, the difference was statistically significant. After treatment, the difference between the two groups was statistically significant. 5. In the incidence of adverse reactions, the two groups in white blood cells, alanine aminotransferase, Both glutamic oxaloacetic transaminase and creatinine were more than 0.05, the difference was not statistically significant. Conclusion: 1. The combination of Yangzhenggui Ling decoction and TP regimen can reduce the serum CA125 level of ovarian cancer patients .2.The self-made Yangzhenggui Ling decoction combined with TP regimen can adjust the level of serum CA125 in patients with ovarian cancer. The expression level of T cells, Improve the immune state of ovarian cancer patients .3.The combination of Yangzhenggui Ling decoction and TP regimen can improve the clinical symptoms and improve the quality of life of ovarian cancer patients with Qi deficiency and blood stasis type.
【學(xué)位授予單位】：黑龍江中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R737.31

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 周云芳 ,蔣麗蓉 ,王薇 ,肖潔;傳染性單核細(xì)胞增多癥和T細(xì)胞免疫[J];臨床兒科雜志;2003年08期

2 李敏;;傳染性單核細(xì)胞增多癥患兒的T細(xì)胞免疫改變[J];現(xiàn)代預(yù)防醫(yī)學(xué);2007年14期

3 鄭翠蘋;楊軍;徐杰;;中西醫(yī)結(jié)合治療非何杰金氏淋巴瘤52例臨床觀察及其對(duì)白細(xì)胞介素-2、可溶性白細(xì)胞介素-2受體、T細(xì)胞及紅細(xì)胞免疫的影響[J];浙江中醫(yī)雜志;2008年12期

4 張曉紅;自身免疫性血小板減少性紫癜的臨床轉(zhuǎn)歸與T細(xì)胞免疫缺陷有關(guān)[J];國外醫(yī)學(xué).輸血及血液學(xué)分冊(cè);1994年03期

5 李卓敏;閆惠平;;原發(fā)性膽汁性肝硬化T細(xì)胞免疫研究進(jìn)展[J];北京醫(yī)學(xué);2013年12期

6 祖慶,王寧玲,瞿志敏,戴海明,徐友和,陶松雪;特發(fā)性血小板減少性紫癜患兒T細(xì)胞免疫功能的變化[J];安徽醫(yī)科大學(xué)學(xué)報(bào);2002年05期

7 黃河;王慧;唐澤麗;楊濱燕;吳長有;;霉酚酸衍生物對(duì)小鼠T細(xì)胞免疫功能的抑制作用[J];免疫學(xué)雜志;2012年09期

8 董毅;吳利先;;T細(xì)胞免疫在抗結(jié)核桿菌感染中的研究進(jìn)展[J];現(xiàn)代生物醫(yī)學(xué)進(jìn)展;2014年18期

9 王寧玲 ,戴海明 ,劉芝璋 ,翟志敏;特發(fā)性血小板減少性紫癜患兒T細(xì)胞免疫功能研究[J];臨床兒科雜志;2003年09期

10 周平,呂楓林,姚詠明,王江,于燕;特發(fā)性血小板減少性紫癜患兒T細(xì)胞免疫功能的變化[J];中華兒科雜志;1999年01期

相關(guān)會(huì)議論文 前10條

1 彭軍;侯明;;特發(fā)性血小板減少性紫癜T細(xì)胞免疫失耐受機(jī)制[A];第12屆全國實(shí)驗(yàn)血液學(xué)會(huì)議論文摘要[C];2009年

2 單保恩;楊興肖;馬鳴;劉麗華;艾軍;趙連梅;張小芳;;大鼠骨髓間充質(zhì)干細(xì)胞對(duì)T細(xì)胞免疫活性的影響[A];2010’全國腫瘤分子標(biāo)志及應(yīng)用學(xué)術(shù)研討會(huì)暨第五屆中國中青年腫瘤專家論壇論文匯編[C];2010年

3 單保恩;楊興肖;馬鳴;劉麗華;艾軍;趙連梅;張小芳;;大鼠骨髓間充質(zhì)干細(xì)胞對(duì)T細(xì)胞免疫活性的影響[A];河北省免疫學(xué)會(huì)第六次免疫學(xué)大會(huì)資料匯編[C];2010年

4 楊興肖;單保恩;;大鼠骨髓間充質(zhì)干細(xì)胞對(duì)T細(xì)胞免疫活性的影響[A];中華醫(yī)學(xué)會(huì)第九次全國檢驗(yàn)醫(yī)學(xué)學(xué)術(shù)會(huì)議暨中國醫(yī)院協(xié)會(huì)臨床檢驗(yàn)管理專業(yè)委員會(huì)第六屆全國臨床檢驗(yàn)實(shí)驗(yàn)室管理學(xué)術(shù)會(huì)議論文匯編[C];2011年

5 劉敏;王運(yùn)律;胡琦;孫思明;劉元霞;張曉峰;;補(bǔ)腎顆粒對(duì)慢性再生障礙性貧血患者T細(xì)胞免疫相關(guān)指標(biāo)影響的臨床研究[A];第八屆全國中西醫(yī)結(jié)合血液病學(xué)術(shù)會(huì)議論文集[C];2007年

6 潘華新;周聯(lián);馬方勵(lì);;增健與營養(yǎng)適、維康素合用對(duì)小鼠T細(xì)胞免疫功能的影響[A];第五屆全國中醫(yī)藥免疫學(xué)術(shù)研討會(huì)——暨環(huán)境·免疫與腫瘤防治綜合交叉會(huì)議論文匯編[C];2009年

7 潘];郭曉玲;蔡圣鑫;董作仁;;G-CSF誘導(dǎo)異基因造血干細(xì)胞移植供者T細(xì)胞免疫耐受機(jī)制初探[A];第12屆全國實(shí)驗(yàn)血液學(xué)會(huì)議論文摘要[C];2009年

8 姚中強(qiáng);李茹;栗占國;;Ⅱ型膠原變構(gòu)肽對(duì)膠原性關(guān)節(jié)炎T細(xì)胞免疫的影響[A];全國自身免疫性疾病專題研討會(huì)暨第十一次全國風(fēng)濕病學(xué)學(xué)術(shù)年會(huì)論文匯編[C];2006年

9 向彩春;熊清s，

本文編號(hào)：1675155